Article info

Download PDFPDF
Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trial

Authors

  1. Correspondence to Professor Gordon C Jayson, Medical Oncology, The Christie NHS Foundation Trust, Manchester, M20 4BX, UK; gordonjayson{at}nhs.net
View Full Text

Citation

Murphy AD, Porter C, White A, et al
Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trial

Publication history

  • Received February 29, 2024
  • Accepted April 25, 2024
  • First published May 9, 2024.
Online issue publication 
July 01, 2024

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.